AATec Medical reports significant progress in company’s first year towards unlocking the therapeutic potential of AAT
Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases: Clinical trial in non-cystic fibrosis bronchiectasis (NCFB) to start in 2025 Pre
AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin
Project for the preclinical development of ATL-105, a recombinant alpha-1 antitrypsin (AAT)-based drug platform for the treatment of inflammatory diseases, viral infections, and ra
AATec Medical and Beurer enter development collaboration for inhaled Alpha-1 Antitrypsin
AATec Medical and Beurer will develop novel inhaler devices for delivering innovative, targeted therapeutics based on recombinant alpha-1 antitrypsin (AAT) to the airways Inhalatio
AATec Medical Announces Creation of Scientific Advisory Board
Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board The BoardR